CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 202 enrolled
Drug / intervention
DETOUR Systemdevice
Likely dose
Not stated in record
Key inclusion· 9
  • Age >18 and ≤90 years
  • Chronic symptomatic lower limb ischemia (Rutherford clinical categories 3, 4, or 5)
  • Symptomatic femoropopliteal chronic total occlusions ≥20 cm (TASC D) or complex TASC C lesions ≥24 cm total length
  • Reference vessel diameter 4.5–6.7 mm
Key exclusion· 13
  • Rutherford clinical category 0, 1, 2, or 6
  • Prior distal amputation (above the transmetatarsal) of target limb
  • Planned major amputation or minor amputation above ankle of target limb
  • History of deep vein thrombosis on either limb

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03119233
NCT03119233N/ACompleted

The Detour Endovascular Technique for Long OcclUsive Fem-pop Revascularization - 2 Clinical Trial

Endologix·interventional·Posted Apr 18, 2017·Updated Apr 2, 2025

In Brief

A clinical study evaluating DETOUR System for Peripheral Arterial Disease. Completed, enrolled 202 participants across 34 sites in 3 countries.

Detailed Summary

Prospective, single-arm, multi-center, international clinical investigation to evaluate the safety and effectiveness of the PQ Bypass System to access, deliver guidewires, and implant stent grafts for a percutaneous femoropopliteal (fem-pop) bypass.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany, Latvia, United States
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedApr 18, 2017
Enrollment StartDec 13, 2017
Primary CompletionDec 22, 2021
Study CompletionNov 13, 2023
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 9.2 years ago

Interventions

DETOUR Systemdevice

The DETOUR System is intended to improve blood flow in patients with peripheral arterial disease in symptomatic femoropopliteal lesions due to chronic total occlusions ≥ 20 cm (TASC D) that can include de novo, restenotic, or in-stent restenotic lesions; or total lesion lengths ≥24 cm that can include chronic total occlusions or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis (complex TASC C).